Putative Mechanism of Hypotensive Action of Platelet‐Activating Factor in Dogs
作者:
Shinya Yamanaka,
Katsuyuki Miura,
Tokihito Yukimura,
Michiaki Okumura,
Kenjiro Yamamoto,
期刊:
Circulation Research
(OVID Available online 1992)
卷期:
Volume 70,
issue 5
页码: 893-901
ISSN:0009-7330
年代: 1992
出版商: OVID
关键词: platelet-activating factor;thromboxane A2;prostacyclin;venodilation
数据来源: OVID
摘要:
We examined the mechanism(s) of hypotensive action of platelet-activating factor (PAF) in anesthetized dogs. PAF (0.5 μg/kg i.v.) caused a biphasic hypotension; the first phase was transient and was accompanied by a decrease in systemic vascular resistance and an increase in cardiac output. Aspirin-DL-lysine, a cyclooxygenase inhibitor, had no effect on this phase. The second phase was characterized by a sustained hypotension caused by a reduction in cardiac output and was accompanied by an increase in systemic and pulmonary vascular resistance. The plasma concentrations of 6-ketopros-taglandinF,. and thromboxane B2also increased. These changes were markedly attenuated by aspirin. Both atrial pressures decreased during the second phase, thereby indicating that the PAF-induced reduction in cardiac output was related to a hindrance in venous return. The hematocrit increased, and aspirin did not affect this change. The extravasation of plasma probably plays a minor role, whereas venodilation would be the primary mechanism of the second-phase hypotension. S-1452, a prostaglandin H2/thromboxane A2antagonist, abolished the PAF-induced pulmonary vasoconstriction but did not block the hypotensive action of PAF. OKY-046, a thromboxane A2synthetase inhibitor, almost completely abolished the PAF-induced pulmonary vasoconstriction and the increase in plasma thromboxane B2level, whereas it potentiated the hypotension and the increase in the plasma concentrations of prostaglandins; aspirin abolished this potentiation. These results suggest that PAF causes hypotension by two different mechanisms: 1) dilatation of resistance vessels independent of prostaglandins and 2) reduction of venous return due to venodilation, as mediated by prostaglandin(s). (Circulation Research1992;70:893–901)
点击下载:
PDF
(1654KB)
返 回